These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28919454)

  • 1. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
    Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
    Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
    Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
    Grisham RN; Berek J; Pfisterer J; Sabbatini P
    Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
    Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
    Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.
    Sabbatini P; Harter P; Scambia G; Sehouli J; Meier W; Wimberger P; Baumann KH; Kurzeder C; Schmalfeldt B; Cibula D; Bidzinski M; Casado A; Martoni A; Colombo N; Holloway RW; Selvaggi L; Li A; del Campo J; Cwiertka K; Pinter T; Vermorken JB; Pujade-Lauraine E; Scartoni S; Bertolotti M; Simonelli C; Capriati A; Maggi CA; Berek JS; Pfisterer J
    J Clin Oncol; 2013 Apr; 31(12):1554-61. PubMed ID: 23478059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abagovomab for ovarian cancer.
    Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
    Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Sabbatini P; Dupont J; Aghajanian C; Derosa F; Poynor E; Anderson S; Hensley M; Livingston P; Iasonos A; Spriggs D; McGuire W; Reinartz S; Schneider S; Grande C; Lele S; Rodabaugh K; Kepner J; Ferrone S; Odunsi K
    Clin Cancer Res; 2006 Sep; 12(18):5503-10. PubMed ID: 17000686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
    Bauerschlag DO; Schem C; Baumann K; Harter P; Hilpert F; Wagner U; du Bois A; Pfisterer J
    Future Oncol; 2008 Dec; 4(6):769-73. PubMed ID: 19086842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
    Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
    Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro study of the antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
    Chang XH; Cui H; Feng J; Yang WL; Li Y; Fu TY; Ye X; Zhu HL; Cheng HY; Cheng YX; Guo HF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 37(5):480-4. PubMed ID: 16224517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Schultes BC; Smith LM; Nicodemus CF
    Clin Cancer Res; 2007 Jul; 13(13):4026; author reply 4026-7. PubMed ID: 17606738
    [No Abstract]   [Full Text] [Related]  

  • 14. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
    Ma J; Zhou L; Wang D
    Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.
    Reinartz S; Pfisterer J; du Bois A; Jackisch C; Baumann KH; Wagner U
    Hum Immunol; 2010 Jan; 71(1):36-44. PubMed ID: 19782714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
    Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
    Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
    Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.
    Madiyalakan R; Yang R; Schultes BC; Baum RP; Noujaim AA
    Hybridoma; 1997 Feb; 16(1):41-5. PubMed ID: 9085127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
    Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
    Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.